Multinational pharma's rush into China-based biotech has reached a record pace in 2026, with nine more deals signed year-to-date than in all of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results